Torres-Guerrero Edoardo, Quintanilla-Cedillo Marco Romano, Ruiz-Esmenjaud Julieta, Arenas Roberto
Sección de Micología, Hospital "Manuel Gea González" Secretaría de Salud, Calz. de Tlalpan 4800, Ciudad de México 14080, Mexico.
Dermatólogo, Clínica Carranza, Chetumal, Quintana Roo, Mexico.
F1000Res. 2017 May 26;6:750. doi: 10.12688/f1000research.11120.1. eCollection 2017.
Leishmaniasis is caused by an intracellular parasite transmitted to humans by the bite of a sand fly. It is endemic in Asia, Africa, the Americas, and the Mediterranean region. Worldwide, 1.5 to 2 million new cases occur each year, 350 million are at risk of acquiring the disease, and leishmaniasis causes 70,000 deaths per year. Clinical features depend on the species of involved and the immune response of the host. Manifestations range from the localized cutaneous to the visceral form with potentially fatal outcomes. Many drugs are used in its treatment, but the only effective treatment is achieved with current pentavalent antimonials.
F1000Res. 2017-5-26
J Am Acad Dermatol. 2015-12
Lancet. 1999-10-2
Parassitologia. 2004-6
Pathol Biol (Paris). 2011-8
J Investig Dermatol Symp Proc. 2001-12
Curr Treat Options Infect Dis. 2015-3-1
J Travel Med. 2009
Iran J Public Health. 2013-12
Pharmaceuticals (Basel). 2025-7-25
PLoS Negl Trop Dis. 2025-7-30
PLoS Negl Trop Dis. 2025-7-28
Infect Disord Drug Targets. 2017
Asian Pac J Trop Med. 2016-10
Rev Inst Med Trop Sao Paulo. 2016-9-22